

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: **Michael T. Migawa et al.** Confirmation No.: **2825**
Serial No.: **10/592,919** Art Unit: **not assigned**
Filed: **7/31/2007** Examiner: **not assigned**

Docket Number: **CORE0037USA**

Title: **COMPOSITIONS AND METHODS FOR OPTIMIZING CLEAVAGE OF RNA
BY RNASE H**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:


**STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE
WITH 37 C.F.R. §§ 1.821 THROUGH 1.825**

I hereby state that the amendments, made in accordance with 37 C.F.R. § 1.825(a), included in the substitute sheet(s) of the Sequence Listing are supported throughout the application, as filed. I hereby state that the substitute sheet(s) of the Sequence Listing does (do) not include new matter.

I hereby state that the substitute copy of the computer readable form, submitted in accordance with 37 C.F.R. § 1.825(b), is the same as the amended paper Sequence Listing.

Respectfully submitted,

Date: 2/9/09


Clifford E. Ford
Registration No. 52,903

ISIS Pharmaceuticals, Inc.
1896 Rutherford Rd.
Carlsbad, CA 92008
Telephone: (760) 931-9200
Facsimile: (760) 603-2784